Literature DB >> 12486156

Pertussis toxin-induced reversible encephalopathy dependent on monocyte chemoattractant protein-1 overexpression in mice.

DeRen Huang1, Marie Tani, Jintang Wang, Yulong Han, Toby T He, Jennifer Weaver, Israel F Charo, Vincent K Tuohy, Barrett J Rollins, Richard M Ransohoff.   

Abstract

In this report we describe pertussis toxin-induced reversible encephalopathy dependent on monocyte chemoattractant protein-1 (MCP-1) overexpression (PREMO), a novel animal model that exhibits features of human encephalopathic complications of inflammatory disorders such as viral meningoencephalitis and Lyme neuroborreliosis as well as the mild toxic encephalopathy that commonly precedes relapses of multiple sclerosis (MS). Overexpression of the mouse MCP-1 gene product (classically termed JE) in astrocytes, the major physiological CNS cellular source of MCP-1, failed to induce neurological impairment. Unexpectedly, transgenic (tg) mice overexpressing MCP-1 at a high level (MCP-1(hi)) manifested transient, severe encephalopathy with high mortality after injections of pertussis toxin (PTx) plus complete Freund's adjuvant (CFA). Surviving mice showed markedly improved function and did not relapse during a prolonged period of observation. Tg mice that expressed lower levels of MCP-1 were affected minimally after CFA/PTx injections, and tg expression of other chemokines failed to elicit this disorder. The disorder was significantly milder in mice lacking T-cells, which therefore play a deleterious role in this encephalopathic process. Disruption of CC chemokine receptor 2 (CCR2) abolished both CNS inflammation and encephalopathy, identifying CCR2 as a relevant receptor for this disorder. Proinflammatory and type 1 cytokines including TNF-alpha, IL-1beta, IFN-gamma, IL-2, RANTES, and IP-10 were elevated in CNS tissues from mice with PREMO. These studies characterize a novel model of reversible inflammatory encephalopathy that is dependent on both genetic and environmental factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12486156      PMCID: PMC6758405     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  29 in total

1.  Expression of astrocytic type 2 angiotensin receptor in central nervous system inflammation correlates with blood-brain barrier breakdown.

Authors:  Laila Füchtbauer; Henrik Toft-Hansen; Reza Khorooshi; Trevor Owens
Journal:  J Mol Neurosci       Date:  2010-04-23       Impact factor: 3.444

2.  Altered hippocampal synaptic transmission in transgenic mice with astrocyte-targeted enhanced CCL2 expression.

Authors:  Thomas E Nelson; Christine Hao; Jessica Manos; R M Ransohoff; Donna L Gruol
Journal:  Brain Behav Immun       Date:  2011-02-26       Impact factor: 7.217

3.  Synaptic plasticity in the hippocampus shows resistance to acute ethanol exposure in transgenic mice with astrocyte-targeted enhanced CCL2 expression.

Authors:  Jennifer G Bray; Kenneth C Reyes; Amanda J Roberts; Richard M Ransohoff; Donna L Gruol
Journal:  Neuropharmacology       Date:  2012-11-16       Impact factor: 5.250

4.  Altered hippocampal synaptic function in transgenic mice with increased astrocyte expression of CCL2 after withdrawal from chronic alcohol.

Authors:  Jennifer G Bray; Kenneth C Reyes; Amanda J Roberts; Donna L Gruol
Journal:  Neuropharmacology       Date:  2018-02-27       Impact factor: 5.250

5.  Estradiol inhibits ongoing autoimmune neuroinflammation and NFkappaB-dependent CCL2 expression in reactive astrocytes.

Authors:  Sébastien N Giraud; Cécile M Caron; Danielle Pham-Dinh; Patrick Kitabgi; Arnaud B Nicot
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

6.  Transgenic mice with increased astrocyte expression of CCL2 show altered behavioral effects of alcohol.

Authors:  Jennifer G Bray; Amanda J Roberts; Donna L Gruol
Journal:  Neuroscience       Date:  2017-04-19       Impact factor: 3.590

7.  CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction.

Authors:  Tomomi Kiyota; Masaru Yamamoto; Huangui Xiong; Mary P Lambert; William L Klein; Howard E Gendelman; Richard M Ransohoff; Tsuneya Ikezu
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

8.  AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice.

Authors:  Tomomi Kiyota; Masaru Yamamoto; Bryce Schroder; Michael T Jacobsen; Russell J Swan; Mary P Lambert; William L Klein; Howard E Gendelman; Richard M Ransohoff; Tsuneya Ikezu
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

9.  Astrocyte- and endothelial-targeted CCL2 conditional knockout mice: critical tools for studying the pathogenesis of neuroinflammation.

Authors:  Shujun Ge; Nivetha Murugesan; Joel S Pachter
Journal:  J Mol Neurosci       Date:  2009-04-02       Impact factor: 3.444

Review 10.  Does inflammation after stroke affect the developing brain differently than adult brain?

Authors:  Zinaida S Vexler; Midori A Yenari
Journal:  Dev Neurosci       Date:  2009-08-11       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.